Genetic predisposition for ovarian cancer development
Abstract
Ovarian cancer is a leading malignancy in the female reproductive system and is responsible for more deaths than any other type of cancer affecting this system. Ovarian cancers can be hereditary or sporadic. Anatomic, cellular, microenvironmental and molecular features of ovarian cancers show a high degree of heterogeneity. Numerous genes implicated in the pathogenesis and progression of ovarian cancers have been identified to date. The majority of these genes act as tumour suppressor genes, oncogenes, or are involved in mismatch repair and double-strand break repair mechanisms. The identification of mutations in cancer susceptibility genes could be a major step forward towards earlier diagnosis, personalized therapy approaches and outcome monitoring. In healthy women, detecting a specific mutated gene can provide a rationale for personalized surveillance, chemopreventive strategies, and prophylactic surgery. Next-generation sequencing offers comprehensive genome analysis, which enables profound understanding and identification of cancer susceptibility genes, and new molecular diagnostic markers and therapeutic targets.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21(5):389–400.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.
Reid F, Bhatla N, Oza AM, Blank SV, Cohen R, Adams T, et al. The World Ovarian Cancer Coalition Every Woman Study: identifying challenges and opportunities to improve survival and quality of life. Int J Gynecol Cancer. 2021;31(2):238–44.
Republička stručna komisija za izradu i implementaciju vodiča dobre kliničke prakse. Nacionalni vodič dobre kliničke prakse za dijagnostikovanje i lečenje karcinoma ovarijuma. Klinički vodič 25/13; 2013.
Veneziani AC, Gonzalez-Ochoa E, Alqaisi H, Madariaga A, Bhat G, Rouzbahman M, Sneha S, Oza AM. Heterogeneity and treatment landscape of ovarian carcinoma. Nat Rev Clin Oncol. 2023;20(12):820–42.
Burke W, Barkley J, Barrows E, Brooks R, Gecsi K, Huber-Keener K, et al. Executive Summary of the Ovarian Cancer Evidence Review Conference. Obstet Gynecol. 2023;142(1):179–95.
Li X, Li Z, Ma H, Li X, Zhai H, Li X, et al. Ovarian cancer: Diagnosis and treatment strategies (Review). Oncol Lett. 2024;28(3):441. doi: 10.3892/ol.2024.14574
Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol. 2011;42(7):918–31.
Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, et al. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res Int. 2015;2015:341723. doi: 10.1155/2015/341723.
Boylan KLM, Petersen A, Starr TK, Pu X, Geller MA, Bast RC Jr, et al. Development of a Multiprotein Classifier for the Detection of Early Stage Ovarian Cancer. Cancers (Basel). 2022;14(13):3077. doi: 10.3390/cancers14133077
Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and Ovarian Cancer: A Comprehensive Review. Cancers (Basel). 2020;12(12):3730. doi: 10.3390/cancers12123730
Huh S, Kang C, Park JE, Nam D, Kim SI, Seol A, et al. Novel Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Uncovered by Data-Independent Acquisition Mass Spectrometry. J Proteome Res. 2022;21(9):2146–59.
Greiser CM, Greiser EM, Dören M. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update. 2007;13:453–63.
Huber D, Seitz S, Kast K, Emons G, Ortmann O. Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet. 2020;301:875–84.
Schrijver LH, Antoniou AC, Olsson H, Mooj TM, Roos-Blom MJ, Azarang L, et al. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. Am J Obstet Gynecol. 2021;225.51.e1–17. doi: 10.1016/j.ajog.2021.01.014
Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371:303–14.
Cook LS, Pestak CR, Leung AC, Steed H, Nation J, Swenerton K, et al. Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk. Br J Cancer. 2017;116:265–9. doi: 10.1038/bjc.2016.400
Wheeler LJ, Desanto K, Teal SB, Sheeder J, Guntupalli SR. Intrauterine device use and ovarian cancer risk: a systematic review and meta-analysis. Obstet Gynecol. 2019;134:791–800.
Karlsson T, Johansson T, Hoglund J, Ek WE, Johansson A. Time-dependent effects of oral contraceptive use on breast, ovarian, and endometrial cancers. Cancer Res. 2021;81:1153–62.
D'Alessandro G, Frigerio M, Barra F, Costantini S, Gustavino C, Ferrero S. Systematic review and meta-analysis on the impact of the levonorgestrel-releasing intrauterine system in reducing risk of ovarian cancer. Int J Gynaecol Obstet. 2022;155:418–24.
Maioru OV, Radoi VE, Coman MC, Hotinceanu IA, Dan A, Eftenoiu AE, et al. Developments in Genetics: Better Management of Ovarian Cancer Patients. Int J Mol Sci. 2023;24(21):15987. doi: 10.3390/ijms242115987
National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program [Internet]. Cancer stat facts: ovarian cancer [cited 2024 Nov 25]. Available from: https://seer.
cancer.gov/statfacts/html/ovary.html.
Kotsopoulos J, Gronwald J, McCuaig JM, Karlan BH, Eisen A, Tung N, et al. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2020;159:820–6.
Feng LP, Chen HL, Shen MY. Breastfeeding and the risk of ovarian cancer: a meta-analysis [published correction appears in J Midwifery Womens Health. 2015 May–Jun;60(3):337. doi: 10.1111/jmwh.12327]. J Midwifery Womens Health. 2014;59(4):428–37.
Royal College of Obstetricians and Gynaecologists. The distal fallopian tube as the origin of non-uterine pelvic high-grade serous carcinomas. Scientific Impact Paper No. 44. RCOG; 2014.
Komata D, Yahata T, Kodama S, Koyama Y, Takeda N, Tajima K, et al. The prevalence of hereditary breast/ovarian cancer risk in patients with a history of breast or ovarian cancer in Japanese subjects. J Obstet Gynaecol Res. 2009;35:912–7.
Soegaard M, Frederiksen K, Jensen A, Hogdall E, Hogdall C, Blaakaer J, et al. Risk of ovarian cancer in women with first-degree relatives with cancer. Acta Obstet Gynecol Scand. 2009;88:449–56.
Suszynska M, Ratajska M, Kozlowski P. BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ∼30,000 cases. J Ovarian Res. 2020;13:50.
Kurman RJ, Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 2008;27(2):151–60.
Mayr D, Hirschmann A, Löhrs U, Diebold J. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol. 2006;103(3):883–7.
Nero C, Ciccarone F, Pietragalla A, Scambia G. PTEN and Gynecological Cancers. Cancers (Basel). 2019;11(10):1458. doi: 10.3390/cancers11101458.
Psyrri A, Kountourakis P, Yu Z, Papadimitriou C, Markakis S, Camp RL, et al. Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets. Ann Oncol. 2007;18(4):709–15.
Wallis B, Bowman KR, Lu P, Lim CS. The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer. Biomolecules. 2023;13(1):159. doi: 10.3390/biom13010159
Kastan MB, Berkovich E. p53: a two-faced cancer gene. Nat Cell Biol. 2007;9(5):489–91.
Flemming A. Cancer: Mutant p53 rescued by aggregation inhibitor. Nat Rev Drug Discov. 2016;15(2):85. doi: 10.1038/nrd.2016.13
Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol. 2007;39(7–8):1476–82.
Astanehe A, Arenillas D, Wasserman WW, Leung PC, Dunn SE, Davies BR, et al. Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. J Cell Sci. 2008;121(Pt 5):664–74.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol. 2020;38:1222–45.
Arts-de Jong M, de Bock GH, van Asperen CJ, Mourits MJ, de Hullu JA, Kets CM. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review. Eur J Cancer. 2016;61:137–45.
Daly MB, Pal T, Maxwell KN, Churpek J, Kohlmann W, AlHilli Z, et al. NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024. J Natl Compr Canc Netw. 2023;21(10):1000–10.
Wooster R, Weber B. L. Breast and ovarian cancer. N Engl J Med. 2003;348(23):2339–47.
Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94(18):1365–72.
Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994;343(8899):692–5.
Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310–6.
Toss A, Laura C. Molecular mechanisms of PARP inhibitors in BRCA-related ovarian cancer. J Cancer Sci Ther. 2013;5(11):409–16.
Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell. 2001;7(2):263–72.
Karami F, Mehdipour P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int. 2013;2013:928562. doi: 10.1155/2013/928562
Gorodetska I, Kozeretska I, Dubrovska A. BRCAGenes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance. J Cancer. 2019;10(9):2109–27.
Albertsen H, Plaetke R, Ballard L, Fujimoto E, Connolly J, Lawrence E, et al. Genetic mapping of the BRCA1 region on chromosome 17q21. Am J Hum Genet. 1994;54(3):516–25.
Le HP, Heyer WD, Liu J. Guardians of the Genome: BRCA2 and Its Partners. Genes (Basel). 2021;12(8):1229. doi: 10.3390/genes12081229
Xie C, Luo J, He Y, Jiang L, Zhong L, Shi Y. BRCA2 gene mutation in cancer. Medicine (Baltimore). 2022;101(45):e31705. doi: 10.1097/MD.0000000000031705
Wu S, Zhou J, Zhang K, Chen H, Luo M, Lu Y, et al. Molecular Mechanisms of PALB2 Function and Its Role in Breast Cancer Management. Front Oncol. 2020;10:301. doi: 10.3389/fonc.2020.00301
Bonilla B, Hengel SR, Grundy MK, Bernstein KA. RAD51 Gene Family Structure and Function. Annu Rev Genet. 2020;54:25–46.
Rizza R, Hackmann K, Paris I, Minucci A, De Leo R, Schrock E, et al. Novel BRCA1 Large Genomic Rearrangements in Italian Breast/Ovarian Cancer Patients. Mol Diagn Ther. 2019;23(1):121–6.
Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS. Why are there hotspot mutations in the TP53 gene in human cancers?. Cell Death Differ. 2018;25(1):154–60.
Schultz KA, Harris A, Messinger Y, Sencer S, Baldinger S, Dehner LP, Hill DA. Ovarian Tumors related to Intronic Mutations in DICER1: A Report from the International Ovarian and Testicular Stromal Tumor Registry. Fam Cancer. 2016;15(1):105–10.
